CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $135.68M, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
193.37BKRW135.68M · vs all stocks (USD)
Revenue (TTM)
1.06BKRW741.01K · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.06xvs all stocks
52-Week Change
58.63%vs all stocks
Market Capitalization
193.37BKRW135.68M · vs all stocks (USD)
Enterprise Value
209.50BKRW147.00M · vs all stocks (USD)
Price to Book (MRQ)
4.58xvs Biotechnology peers
Enterprise to Revenue
198.37xvs Biotechnology peers
Enterprise to EBITDA
-13.73xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-285.92%vs Biotechnology peers
Return on Assets (TTM)
-17.85%vs Biotechnology peers
Return on Equity (TTM)
-50.25%vs Biotechnology peers
Revenue (TTM)
1.06BKRW741.01K · vs all stocks (USD)
Revenue per Share (TTM)
58.38KRWUpdated Jul 15, 2026Gross Profit (TTM)
1.04BKRW731.46K · vs all stocks (USD)
EBITDA (TTM)
-15.25BKRW-10.70M · vs all stocks (USD)
Net Income (TTM)
-17.13BKRW-12.02M · vs all stocks (USD)
Operating Cash Flow (TTM)
-14.54BKRW-10.20M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-16.48BKRW-11.57M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
7.10MKRWFY2025 · Dec 31, 2025Gross Profit
7.10MKRWFY2025 · Dec 31, 2025Operating Income
-16.50BKRW-11.58M · vs all stocks (USD)
Pre-tax Income
-18.11BKRWFY2025 · Dec 31, 2025Net Income
-18.11BKRWFY2025 · Dec 31, 2025EBIT
-16.52BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-15.30BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
10.16BKRWFY2025 · Dec 31, 2025Other Operating Expenses
1.41BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
471.54MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
1.60BKRWFY2025 · Dec 31, 2025EPS (Basic)
-1.12KKRWFY2025 · Dec 31, 2025EPS (Diluted)
-1.12KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
16.17MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
16.17MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-18.11BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-17.59BKRWFY2025 · Dec 31, 2025Free Cash Flow
-17.60BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.04BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-18.11BKRWFY2025 · Dec 31, 2025Stock-based Compensation
28.67MKRWFY2025 · Dec 31, 2025Other Non-cash Items
786.78MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
11.03MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-304.67MKRWFY2025 · Dec 31, 2025Capital Expenditures
-4.15MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-19.25MKRWFY2025 · Dec 31, 2025Purchase of Investments
-20.63BKRWFY2025 · Dec 31, 2025Sale of Investments
27.00BKRWFY2025 · Dec 31, 2025Other Investing Activity
-103.90MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
6.26BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
3.00BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-16.99BKRWFY2025 · Dec 31, 2025Other Financing Charges
-3.77MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
7.36BKRWFY2025 · Dec 31, 2025Shares Outstanding
21.92MSharesUpdated Jul 15, 2026Float Shares
19.57MSharesUpdated Jul 15, 2026% Held by Insiders
16.53%vs all stocks
% Held by Institutions
0.28%vs all stocks
Total Cash (MRQ)
20.21BKRW14.18M · vs all stocks (USD)
Total Cash per Share (MRQ)
935.42KRWUpdated Jul 15, 2026Total Debt (MRQ)
11.90BKRW8.35M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2860xvs Biotechnology peers
Current Ratio (MRQ)
2.10xvs Biotechnology peers
Book Value per Share (MRQ)
1.93KKRWUpdated Jul 15, 2026Total Assets
53.21BKRW37.34M · vs all stocks (USD)
Total Current Assets
24.52BKRWFY2025 · Dec 31, 2025Total Liabilities
16.12BKRWFY2025 · Dec 31, 2025Total Non-current Assets
28.69BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
3.37BKRWFY2025 · Dec 31, 2025Total Current Liabilities
12.75BKRWFY2025 · Dec 31, 2025Cash Equivalents
4.04BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.04BKRWFY2025 · Dec 31, 2025Other Short-term Investments
20.00BKRWFY2025 · Dec 31, 2025Accounts Receivable
0.00KRWFY2025 · Dec 31, 2025Short-term Debt
10.28BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-610.00KRWFY2025 · Dec 31, 2025Long-term Debt
3.08BKRWFY2025 · Dec 31, 2025Common Stock (Book)
10.50BKRWFY2025 · Dec 31, 2025Retained Earnings
-106.49BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
37.09BKRW26.02M · vs all stocks (USD)
52-Week Low
3.60KKRWUpdated Jul 15, 202652-Week High
20.75KKRWUpdated Jul 15, 202652-Week Change
58.63%vs all stocks
Beta
2.06xvs all stocks
50-Day MA
13.39KKRWUpdated Jul 15, 2026200-Day MA
10.99KKRWUpdated Jul 15, 2026Avg 10-Day Volume
104.14KSharesUpdated Jul 15, 2026Avg 30-Day Volume
184.79KSharesUpdated Jul 15, 2026Diluted EPS (TTM)
-1.12KKRWUpdated Jul 15, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: 0.00
Financial Health
Altman Z-Score 3.64: safe zoneNotable
Altman Z-Score: 3.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $135.68M, lower than 95% of all stocks globallySignificant
Market cap (USD): 135,683,272.44Global P5: 269,387,740.27
Revenue is $741,010, lower than 95% of all stocks globallySignificant
Revenue (USD): 741,010.126Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Scancell Holdings Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Futurechem Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enlivex Therapeutics Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Yungjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HLB Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Longda Meishi Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated